.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical advancements suggest that biological drugs for Sjögren disease could transform the management of salivary dysfunction. Sjögren disease often causes systemic complications, with dry mouth being a hallmark symptom. Researchers are now evaluating how novel biological agents target the underlying pathophysiology of this condition. Consequently, these therapies may offer new hope for patients struggling with persistent hyposalivation.
A systematic review analyzed fourteen randomized clinical trials involving 1,772 patients to assess therapeutic efficacy. The studies focused on various agents, including rituximab, iscalimab, and human interferon (IFN)-α. Specifically, four trials reported that rituximab and iscalimab led to a significant increase in unstimulated whole salivary flow. Furthermore, participants experienced a noticeable improvement in dry mouth sensations. These findings indicate that these agents may restore glandular activity more effectively than traditional palliative care. However, other biologicals like infliximab and tocilizumab did not demonstrate similar benefits in this review. Most patients tolerated the treatments well, with the researchers observing no relevant adverse effects across the included studies.
The potential benefits of these therapies highlight a shifting landscape in autoimmune treatment. Moreover, the integration of biological drugs into clinical practice requires careful patient selection. While rituximab and iscalimab show promise, larger and more standardized trials are still necessary. This will help doctors determine the optimal timing and dosage for these interventions. Currently, these drugs provide a valuable alternative when standard secretagogues fail to provide relief. Additionally, clinicians should remain updated on emerging data regarding long-term safety and efficacy profiles.
Research indicates that rituximab, iscalimab, and human interferon-α are among the most promising biological agents for improving salivary flow and reducing xerostomia symptoms.
The recent systematic review observed no relevant adverse effects in the clinical trials studied, suggesting that these agents are generally well-tolerated by patients.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship between the reader and the author. Always consult with a qualified healthcare professional for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Seoane-Romero JM et al. Effectiveness of biological drugs in the treatment of xerostomia and salivary hypofunction in patients with Sjögren disease. J Am Dent Assoc. 2026 Mar 10. doi: undefined. PMID: 41805268.
Pijpe J, Vissink A, Kallenberg CG. The Future of Biologic Agents in the Treatment of Sjögren's Syndrome. Rheum Dis Clin North Am. 2016;42(3):519-533. doi: 10.1016/j.rdc.2016.03.010.
Grader-Beck T. Novel Biologic for Sjogren's Clears Penultimate Hurdle. MedPage Today. October 30, 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systematic review highlights the effectiveness of biological drugs like rituximab and iscalimab in treating salivary dysfunction in Sjögren disease....
6 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
